Pro Medicus (ASX: PME) – Pro Medicus signs 128M NYC hospital deal

Pro Medicus Limited has secured a significant 10-year contract valued at A$128 million with NYC Health + Hospitals, one of the largest public health systems in the United States. The deal represents a substantial validation of the company’s cloud-based enterprise imaging platform and signals growing adoption of Visage 7 solutions among major healthcare providers operating at scale.

The contract encompasses the full suite of Visage 7 products, including the Visage 7 Viewer for image analysis, Visage 7 Workflow for clinical operations, and Visage 7 Open Archive for data management. NYC Health + Hospitals will implement this unified diagnostic imaging platform across its operations, replacing legacy Picture Archiving and Communication Systems (PACS) infrastructure. The scope includes migration of archived imaging data from existing legacy systems onto the Visage 7 Open Archive, alongside integration of image distribution capabilities with NYC Health + Hospitals’ electronic health records environment. This comprehensive implementation demonstrates the breadth of Pro Medicus’ offerings in enterprise imaging solutions.

The contract operates under a transaction-based licensing model. Under this structure, Pro Medicus generates revenue according to actual usage volumes within the healthcare system. This approach provides a mechanism for revenue to scale beyond the base A$128 million contract value, creating upside potential for the company if clinical adoption and transaction volumes exceed baseline assumptions. This model aligns Pro Medicus’ economics directly with value delivered to the customer and suggests the company and its partner have confidence in driving meaningful adoption across the institution.

NYC Health + Hospitals operates 11 hospitals and numerous affiliated clinics, serving millions of patients across New York City’s five boroughs. The scale and profile of this institution as a leading public healthcare system elevates the strategic importance of this contract. Successful implementation could establish important reference credentials for other major hospital networks evaluating enterprise imaging platforms. The contract demonstrates Pro Medicus’ ability to compete effectively against established vendors in winning complex, mission-critical deployments.

Planning for the rollout commences immediately, with management targeting a go-live in late third quarter 2027. Pro Medicus indicated it will leverage its established cloud-based implementation methodology, suggesting the company has refined and scalable processes for large-scale deployments based on prior customer projects. The 12 to 18 month timeline to full operational status represents a realistic implementation horizon for an organisation of NYC Health + Hospitals’ complexity and size.

A rules-based approach to leveraged ETFs

See how our quantitative strategy works and who it suits.

Explore the strategy

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

For investors, execution against the go-live timeline will be a key monitoring point, as will the actual transaction volumes that materialise once the system operates in production. Future updates on implementation progress, clinical adoption rates, and customer feedback on platform performance will offer insights into the contract’s value creation trajectory. The announcement is price sensitive and has been flagged as material by the ASX.

View the full ASX announcement (PDF)

About Pro Medicus Limited (ASX: PME)

Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.

Learn to trade with a plan

Our free 5-day course covers entries, exits and risk management.

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…

« Older Entries

Unlock every article for free

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.